about
Genetic determinants and potential therapeutic targets for pancreatic adenocarcinomaCancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear familyA mitotic function for the high-mobility group protein HMG20b regulated by its interaction with the BRC repeats of the BRCA2 tumor suppressorGAS, a new glutamate-rich protein, interacts differentially with SRCs and is involved in oestrogen receptor functionFounder populations and their uses for breast cancer genetics.POT1 loss-of-function variants predispose to familial melanomaPALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility geneRecent progress in pancreatic cancerMultidisciplinary meeting on male breast cancer: summary and research recommendationsBRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarianMolecular tumor profiling: translating genomic insights into clinical advancesFounder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancerRole of BRCA gene dysfunction in breast and ovarian cancer predisposition.Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status13th General Meeting of The Breast Cancer Linkage Consortium, November 29-December 1, 1999, Amsterdam, The NetherlandsFuture possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers.BRCA1/2 mutation screening and LOH analysis of lung adenocarcinoma tissue in a multiple-cancer patient with a strong family history of breast cancerA comparison of genetic risk score with family history for estimating prostate cancer riskPancreatic Cancer GeneticsEpidemiology and Inherited Predisposition for Sporadic Pancreatic AdenocarcinomaBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsInherited pancreatic cancer syndromesThe complexities of epidemiology and prevention of gastrointestinal cancersBrca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesisGermline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteinsOverexpression of RAD51 occurs in aggressive prostatic cancerAssociations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutationsSome molecular and clinical aspects of genetic predisposition to malignant melanoma and tumours of various site of originFamilial malignant melanoma - overviewPALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSBrca2 deficiency in the murine small intestine sensitizes to p53-dependent apoptosis and leads to the spontaneous deletion of stem cellsRare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancerIdentification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.Screening for Pancreatic Cancer.High risk factors of pancreatic carcinoma.Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.Classifying Variants of Undetermined Significance in BRCA2 with protein likelihood ratios.Uterine serous carcinoma: increased familial risk for lynch-associated malignancies
P2860
Q21129230-48A5B126-BAF7-4785-A9B3-C05319B8EB2BQ21144736-90AD024C-A8F9-484A-BA00-219DD64F2ABDQ24297103-199F0E06-136E-4781-8717-C50A1CBFDAE9Q24318938-FF67B41C-51C7-4B50-8B92-0A760073E971Q24544179-104C0A15-EE84-454E-A2CD-688F286CB663Q24563091-86B25B88-9A82-4B69-86C1-9E9E23397F7EQ24615080-997E0CF9-9093-4362-B5F4-2A3512C4A9F1Q24626346-01117B8E-4CA4-41A3-829E-AC89C79B80A5Q24631800-65B72BB9-310F-433F-B4DA-676A4787387EQ24672251-D04A6434-1F0D-47FA-8F82-EA8EA5EBB8E9Q24797250-72F2FC45-02B9-4AD1-96D5-7C90B0BD2CA8Q24798248-C1D45D27-A2B9-4E17-BAFE-F9E23C3045D2Q24800677-DF1DC74E-B174-4CD8-B080-30E6DBF85FA4Q24802534-95234B67-F01A-4396-BDD7-147024010C30Q24803103-C5A5C8AF-BB53-4F5E-8583-FB852FF1961DQ24803349-E5876EA0-DEB4-4822-A450-A36E31F70D81Q24805707-FCD943C4-CE06-4551-A6A5-8ECD47BA3A5DQ26752649-6D9C78F9-F974-4EE3-871B-B10FF06C7469Q26765235-52F57153-AE14-40C7-9E72-8FE1833664C3Q26801418-547541B6-3775-4342-8F11-B01972A0D08BQ26852274-6C931214-F560-4FAA-A0D7-6BE50CFA72EEQ26853530-EAC452EB-B82A-4295-90A5-A17D0AA3FD20Q26865429-A5EC9D90-B981-480C-A79D-190A3B54EF94Q27347240-A0182317-BBD0-46A9-8021-92B5391397E8Q27852185-03EC73ED-09AC-4C9C-98FD-D6C0E0CAEBC0Q28073673-59EC96BF-EF45-4E0B-B9C3-75D017E9F781Q28085364-6047BA61-3F34-45B0-B3CB-E4EFA47EFEBDQ28267299-9C3852C9-6099-43B1-BAD5-52124241D498Q28386233-E2B105B9-BCC1-4C60-86D5-D3C4B47EE905Q28390768-7439EFE3-31C2-41E6-8F41-48C7F9A20092Q28391589-1627A77E-1A24-414D-90A0-0F2EF827BC17Q28584533-F3AE1A5C-8D9A-414F-9342-F1CCC1CE6E99Q28592124-C7A585D3-0C9B-4696-BE74-EA46187587B7Q28943461-EFAE31E3-CD24-44F6-85B9-6DA7651EE97FQ29417155-1C4D9E67-9D9B-4910-AA06-D4F11E18A425Q30240971-96C75179-1128-445F-90E0-8C6F0741FF9EQ30249161-B74E349B-EB88-46A4-814A-446A0298106EQ30361333-5561B246-9C41-466E-8436-CBF0ED4F9598Q30373569-13923A31-DB62-4B54-A5CC-A9A6CEBF929FQ30422098-7CDB4FD8-4EF9-4D9E-AE65-BFBA9FC27C1C
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Cancer risks in BRCA2 mutation carriers.
@ast
Cancer risks in BRCA2 mutation carriers.
@en
Cancer risks in BRCA2 mutation carriers.
@nl
type
label
Cancer risks in BRCA2 mutation carriers.
@ast
Cancer risks in BRCA2 mutation carriers.
@en
Cancer risks in BRCA2 mutation carriers.
@nl
prefLabel
Cancer risks in BRCA2 mutation carriers.
@ast
Cancer risks in BRCA2 mutation carriers.
@en
Cancer risks in BRCA2 mutation carriers.
@nl
P2860
P356
P1476
Cancer risks in BRCA2 mutation carriers.
@en
P2093
Breast Cancer Linkage Consortium
P2860
P304
P356
10.1093/JNCI/91.15.1310
P407
P577
1999-08-01T00:00:00Z